EDTA, CALCIUM DISODIUM
General Information
Mainterm | EDTA, CALCIUM DISODIUM |
Doc Type | ASP |
CAS Reg.No.(or other ID) | 62-33-9 |
Regnum |
175.105 176.170 166.110 169.115 169.140 169.150 73.1 155.200 155.201 161.173 172.120 172.135 |
From www.fda.gov
Toxicity Profile
Route of Exposure | Poorly absorbed from the gastrointestinal tract. Well absorbed following intramuscular injection. |
---|---|
Mechanism of Toxicity | The pharmacologic effects of edetate calcium disodium are due to the formation of chelates with divalent and trivalent metals. A stable chelate will form with any metal that has the ability to displace calcium from the molecule, a feature shared by lead, zinc, cadmium, manganese, iron and mercury. The amounts of manganese and iron metabolized are not significant. Copper is not mobilized and mercury is unavailable for chelation because it is too tightly bound to body ligands or it is stored in inaccessible body compartments. The excretion of calcium by the body is not increased following intravenous administration of edetate calcium disodium, but the excretion of zinc is considerably increased. |
Metabolism | Almost none of the compound is metabolized. |
Toxicity Values | Inadvertent administration of 5 times the recommended dose, infused intravenously over a 24 hour period, to an asymptomatic 16 month old patient with a blood lead content of 56 mcg/dl did not cause any ill effects. Edetate calcium disodium can aggravate the symptoms of severe lead poisoning, therefore, most toxic effects (cerebral edema, renal tubular necrosis) appear to be associated with lead poisoning. Because of cerebral edema, a therapeutic dose may be lethal to an adult or a pediatric patient with lead encephalopathy. Higher dosage of edetate calcium disodium may produce a more severe zinc deficiency. |
Lethal Dose | None |
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
Minimum Risk Level | None |
Health Effects | None |
Treatment | None |
Reference |
|
From T3DB